Skip to main content
Premium Trial:

Request an Annual Quote

Sony DADC to Manufacture MyCartis Biomarker Analysis Cartridges

NEW YORK (GenomeWeb) – MyCartis announced today that it has signed a deal to have the microfluidic assay cartridges for its Evaluation multiplex biomarker analysis platform manufactured at Sony DADC Biosciences' facility in Salzburg, Austria.

MyCartis, a joint venture of Biocartis and Pronota, was launched in late 2014. The Evaluation platform is intended for simultaneous analysis of multiple protein and nucleic acid markers.

Under the newly announced agreement, Sony DADC BioSciences will manufacture the cartridges for use in clinical and pharmaceutical research applications at its Salzburg, Austria facility. Specific terms of the arrangement were not disclosed.

"The collaboration between the two companies brings together a broad range of knowledge and experience," MyCartis CEO Joris Schuurmans said in a statement.

"From a manufacturing perspective, the project enhances our capabilities in both injection molding and bonding of microfluidic consumables in microtiter plate format — the de facto industry standard," added Werner Balika, engineering manager at Sony DADC BioSciences.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.